Health
Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma – News-Medical.Net
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency…
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference. NAVIGATOR (NCT03347279) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial.
Tezepelumab offers new therapeutic opportunities for patients…
-
Business22 hours ago5 things to watch on the ASX 200 on Monday 1 September 2025
-
Noosa News22 hours agoStar Brisbane cricketer finds home in suburb with shocking popularity rise
-
Noosa News10 hours agoMassive wind farm project in Queensland axed amid community backlash
-
Business13 hours agoIAG shares are racing higher today. Here’s why